VIP has the most misleading name in peptide pharmacology — it's neither primarily vasoactive nor intestinal. What it actually does is orchestrate immune tolerance: programming dendritic cells to generate regulatory T cells, shifting macrophages from inflammatory to reparative states, and maintaining gut barrier integrity. It operates through two receptor subtypes (VPAC1 and VPAC2) that switch depending on immune activation state — VPAC1 on resting cells dampens acute inflammation; VPAC2 on activated T cells drives long-term tolerance programming. VIP has more human trial data than most peptides in active research, including a 471-patient Phase 3 (IV in COVID-19 ARDS, stopped for futility), but with a ~1-minute plasma half-life, IV bolus dosing is pharmacokinetically irrational, and Phase 2 data with inhaled/nebulized delivery were positive — the "failure" is better understood as a delivery-route problem than a drug problem.

What Is VIP?

A 28-amino-acid neuropeptide discovered in 1970 as a vasodilator isolated from porcine gut, now understood as an immune tolerance orchestrator — regulating dendritic cell programming, regulatory T-cell expansion, gut barrier integrity, and circadian clock synchronization across the central and peripheral nervous systems. The misleading name persists because endocrinology naming freezes to the first observed function. VIP is expressed throughout the CNS, enteric nervous system, thymus, lung, and immune organs, and belongs to the secretin-glucagon superfamily alongside PACAP.

VPAC1 and VPAC2: The Receptor Biology

VIP acts through two G-protein coupled receptors with distinct immune roles. VPAC1 (constitutive on resting T cells, monocytes, neutrophils) drives acute anti-inflammatory signaling — binding on macrophages/monocytes suppresses TNF-alpha, IL-6, and IL-12 via cAMP/PKA activation, where CREB competes with NF-kB for the shared coactivator CBP while stabilizing IkB/NF-kB complexes. When T cells activate, VPAC1 drops and VPAC2 rises — a receptor switch shifting VIP from inflammation control to expansion/maintenance of CD4+CD25+FoxP3+ regulatory T cells. VPAC2-knockout mice develop exacerbated autoimmune encephalomyelitis with reduced Tregs and impaired suppressive function. Human mast cells express only VPAC2; resting monocytes and neutrophils only VPAC1 — so VIP delivers context-dependent instructions calibrated to each cell's activation state. This is the fire-extinguisher-vs-architect distinction: VPAC1 puts out the fire; VPAC2 redesigns the building.

Immune Tolerance Orchestration

VIP generates tolerogenic dendritic cells (low CD40/CD80/CD86, low pro-inflammatory cytokines, high IL-10) that actively generate regulatory T cells — both CD4+ and notably CD8+ Tregs with a CD28-negative/CTLA4-positive phenotype (VPAC1-mediated via cAMP/PKA inhibition of NF-kB). It biases macrophage polarization from inflammatory M1 toward reparative M2 (redirection, not suppression — attack mode to repair mode). It downregulates TLR-2 and TLR-4 on colonic tissue via PU.1 inhibition, raising the activation threshold so the immune system tolerates commensal bacteria while staying responsive to pathogens. This is coordinated tolerance programming across multiple immune lineages — "anti-inflammatory" captures one consequence while missing the architecture.

The Gut-Brain-Immune Axis

The enteric nervous system is the body's largest VIP source. VIP-knockout mice show distorted crypt architecture, reduced goblet cells, defective epithelial turnover, increased permeability, and more severe colitis — exogenous VIP rescues the phenotype (enhanced tight junctions, stimulated mucus, recruited protective innate lymphoid cells). Microbiome: VIP deficiency alters Firmicutes-to-Bacteroidetes ratios and reduces biodiversity, positioning VIP as a regulator of the microbial ecosystem. Feeding-responsive immune activation: a 2022 study showed enteric neurons release VIP in response to feeding, potentiating ILC2/ILC3 cytokine production — coupling nutritional status to mucosal defense and increasing resistance to helminth and enterobacterial infection. To increase VIP naturally: regular feeding patterns, morning circadian light, and vagal-tone exercises (controlled breathing, cold exposure) support endogenous signaling but can't replace exogenous administration in deficiency states.

Circadian Synchronization

VIP is the primary synchronizing neuropeptide in the suprachiasmatic nucleus (SCN), the brain's master clock — VIP neurons coordinate firing across SCN populations and align peripheral clocks with the light-dark cycle; without VIP, neurons lose synchrony and circadian output fragments. This positions VIP as a Tier-3 circadian intervention (after light/meal timing and sleep architecture). The SCN role is well-characterized in animals, but human circadian intervention trials with exogenous VIP haven't been conducted — AM dosing reflects the rationale of reinforcing the morning cortisol peak.

Clinical Evidence

A broader human evidence base than most research peptides, telling an honest story of large trials missing endpoints alongside smaller positive signals — with route of administration emerging as possibly mattering more than the molecule.

COVID-19/respiratory failure: TESICO (n=471, IV aviptadil) stopped for futility; a Phase 2b/3 (n=196) missed its primary endpoint but showed a pre-specified 60-day survival signal (OR 2.0) with reduced IL-6; an 80-patient inhaled-aviptadil RCT significantly reduced hospital stay (7.8 vs 10 days) and improved oxygenation. The IV-vs-inhaled divergence is the key finding — IV's ~1-minute half-life limits exposure, while inhaled delivery concentrates VIP at the pulmonary epithelium where VPAC receptors are dense. Sarcoidosis: a Phase II (n=20, nebulized) was safe, reduced TNF-alpha by bronchoalveolar macrophages, and increased CD4+CD25+FoxP3+ Tregs — the first controlled human demonstration of VIP's immunoregulatory effect. Pulmonary hypertension: inhaled VIP produced pulmonary vasodilation; 3–6 months reduced mean PA pressure from 59 to 46 mmHg. CIRS/mold illness: an 18-month open-label trial (n=20) normalized TGF-beta1, C4a, MMP-9 with NeuroQuant MRI improvements and increased Tregs; a larger >10,000-patient cohort shows consistent findings but comes from a single practitioner-researcher without independent replication. IBD: strong TNBS-colitis preclinical data but no completed human efficacy trial — the barrier is pharmacokinetic (rapid degradation, dose-limiting hypotension).

Delivery, Dosing, and Safety

Most commonly intranasal (50–100 mcg per dose) in research contexts — direct CNS access via olfactory/trigeminal pathways, avoiding rapid systemic degradation; begin low and titrate. Subcutaneous (circadian research) is an alternative. Nanomedicine systems (VIP-SSM micelles, oral colonic capsules) show preclinical promise at lower doses without hypotensive toxicity but aren't clinically available. Safety: generally favorable at intranasal doses (mild transient flushing most common); at higher IV doses, dose-limiting hypotension and tachycardia; no dependency/withdrawal reported. VIP can theoretically increase susceptibility to intracellular pathogens — a mechanistically consistent trade-off of tolerance programming. Blood testing: elevated VIP suggests VIPoma or counter-regulatory inflammatory release; low VIP appears in CIRS cohorts (Shoemaker panel). Specimens require plasma on ice with rapid processing (VIP degrades fast ex vivo). Not FDA-approved for any indication.

Evidence Hierarchy

Tier 2 (controlled human data, clear signals): pulmonary immune modulation is strongest — sarcoidosis TNF-alpha reduction and Treg expansion, pulmonary-hypertension hemodynamic improvement, inhaled-aviptadil reduced hospital stay (all inhaled/nebulized). CIRS marker normalization is Tier-2 observational with the single-practitioner caveat. Tier 2 with caveats: the IV COVID-19 data (TESICO futility, Phase 2b/3 missed primary but 60-day survival signal) may reflect route/timing failure, not biology. Tier 3 (strong mechanism, limited human data): IBD (strong preclinical, no completed human trial), circadian synchronization (animal SCN physiology, untested in humans), gut barrier/microbiome (knockout/feeding studies). The translational lesson: VIP shows strong mechanism can fail to translate when delivery doesn't match the target — and that failure can be instructive rather than terminal.